

ESTIA HEALTH Sydney Office Level 9, 227 Elizabeth Street Sydney NSW 2000 T 02 9265 7900 E info@estiahealth.com.au

16 August 2019

Cheng Tang ASX Listings Compliance Rialto Tower, 525 Collins Street Melbourne VIC 3000

Dear Cheng,

### Re: Appendix 3Y – Change of Director's Interest Notice

The Company wishes to notify the ASX that it inadvertently neglected to lodge an Appendix 3Y for a director upon the completion of an on-market trade on 05 December 2018.

We now enclose the Appendix 3Y for lodgement and have outlined below an explantion on why it has been lodged late.

### 1. Explanation as to why was the Director's Notice was lodged late

The Appendix 3Y was prepared upon the completion of an on-market purchase of Estia Health Limited shares in accordance with requirements, and filed for lodgement. The Director's Interest Register maintained internally was also updated. However, the Notice was inadvertently not released to the ASX.

The failure to lodge the Appendix 3Y in this instance was purely as a result of oversight. This oversight was uncovered when compiling supporting documentation for the 2019 year end audit.

# 2. Company arrangements in place with directors to ensure that it is able to meet its disclosure obligations under listing rule 3.19A

- (a) Each director is informed of ASX disclosure requirements upon their appointment.
- (b) The Company has entered into agreements with each of its directors, which places an obligation on the directors to notify the Company of interests and any changes thereto so that the ASX Appendices can be lodged. Notification of any changes in a director's direct or indirect interest in Company securities is also required under the Company's market disclosure policy.
- (c) Standing items on the agenda of board meetings are director's shareholding register, director's interest register and trading window; and
- (d) Any director wishing to trade in the Companys securities must first obtain the consent to do so from the Chairman and Company Secretary in accordance with the Company's security trading policy. Where approved, the director must continue to comply with other requirements set out in that policy in connection with the dealing.

### 3. Additional Steps the Company intends to take to ensure compliance with Listing Rules 3.19B

The Company considers that the current arrangements as outlined aove are adequate and notes that the late lodgement of the abovementioned Appendix 3Y was a result of an inadvertent oversight.

Yours sincer

Leanne Raiph Company Secretary

# Appendix 3Y

Rule 3.19A.2

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Estia Health Limited	
ABN 37 160 986 201	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Warwick Smith
Date of last notice	10 May 2017

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest comprises a relevant interest under section 608(3) of the Corporations Act 2001 (Cth) – registered holder is HSBC Custody Nominees (Australia) Pty Ltd as custodian for Relbia Pty Ltd as trustee for the Warwick Smith Super Fund	
Date of change	05 December 2018	
No. of securities held prior to change	45,000 fully paid ordinary shares	
Class	Fully paid ordinary shares	
Number acquired	45,000	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$2.2336 per share	

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change	90,000 fully paid ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

## Part 3 – <sup>+</sup>Closed period

Were the interests in the securities or contracts	No
detailed above traded during a <sup>+</sup> closed period	
where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.